Introduction
============

Drug discovery for a specific target is a long process that starts from hit finding: in the past high throughput screening (HTS) of huge compound libraries was the most common process in pharmaceutical companies. However, the chemical space that the HTS can reach is restricted to the molecules that were previously synthesized and included in the screened library. This certainly precludes the discovery of new compounds, as the chemical space is much wider and the use of limited knowledge makes the hit discovery challenging ([@B8]; [@B38]).

To overcome these disadvantages, computational techniques can be applied in order to speed up the process of drug design and to perform *de novo* drug design. One of the most popular methods is virtual screening, that is the identification of possible candidates for assays by considering their molecular properties (ligand-based) and/or their interactions with the macromolecular binding partner (typically a protein) when its structure is available (structure-based) ([@B18]; [@B46]; [@B15]; [@B47]). Different virtual compound libraries can be designed, depending on the target properties and on the desired pharmacokinetics ([@B20]). Therefore, fragment-based and relatively small focused libraries have found great success: a wider chemical space is covered by virtually assembling many different building blocks as in combinatorial synthesis ([@B6]; [@B38]) or by building compounds directly starting from the structure complex with the first fragment ([@B44]).

Furthermore, virtual libraries can be properly designed in order to identify active compounds, which also exhibit suitable ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties ([@B11]). The Lipinski's rule of five ([@B21]) helps in identifying orally active compounds, but does not fully describe all facets of druggability. For instance, today the *in silico* assessment of molecular toxicity is still challenging ([@B39]; [@B35]), but at the same time necessary to establish early and *in silico* if a molecule could cause toxic side effects, rather than in the later preclinical phase by experimental assays, which are expensive and time consuming ([@B32]). On one side, it is undoubted that side effects take place when a molecule is active on multiple targets and, hence, by definition promiscuous ([@B48]). On the other side, promiscuity can represent also an advantage, where the goal of the drug development is to obtain a polypharmacological effect, especially in the treatment of diseases that involve multiple targets ([@B1]; [@B36]).

To this purpose, the computation of molecular properties has been established not only to discriminate between inactive and active, weak and potent compounds, but also between promiscuous and selective ligands. For instance, [@B23] showed that target selectivity increases with the number of chiral centers and with higher molecular complexity, described as fraction of carbon sp^3^ atoms. Moreover, the presence of amines and high clogP values negatively affect target selectivity ([@B22]). Indeed, many promiscuous compounds are positively charged at physiological pH, as emerged also from the analysis of a Roche dataset ([@B33]).

With the recent identification of "dark chemical matter" (DCM) as promising starting point for drug discovery ([@B24]; [@B50]), chemical properties of this potentially highly selective compound species are in the focus of interest. [@B50] use descriptors based on the two-dimensional (2D) compound structures and describe subtle shifts in their distributions toward higher solubility (logS), lower hydrophobicity (logP), smaller molecular weight (MW) and lower amount of rings for DCM versus compounds that are frequently active in HTS assays ([@B50]). They define DCM as molecules that are inactive in at least 100 assays, presuming that these compounds would hit only few possible targets. However, there are compounds, which are listed as DCM, but they are active on many different targets. For example, CID1048281 (Supplementary Figure [1](#SM1){ref-type="supplementary-material"}) is considered DCM because it is inactive in more than 650 assays, but it is also active in other six assays in PubChem, which test the activity on unrelated targets (RAR-related orphan receptor gamma, aldehyde dehydrogenase, tyrosyl-DNA phosphodiesterase, ATPase, bromodomain adjacent to zinc finger domain and shiga toxin).

On the other side, many assays may be available for the same target and the number of negative test outcomes does not necessarily correctly depict target selectivity. For example, there are 245 small-molecule bioassays reported on PubChem for the adrenoreceptor beta 1 and more than 350 for the beta 2 subtype. Moreover, most of these bioassays are not specific for a receptor subtype or are simply confirmatory. In order to overcome this pitfall, [@B50] filtered the set of bioassays by removing redundant readouts for the same target.

As shown, it is extremely hard to determine the target selectivity of a molecule solely on the base of its assay positive or negative outcomes. For this reason, we propose an alternative classification of active molecules, on the base of the number of targets they hit, in order to investigate target selectivity and/or polypharmacology in the early phase of the drug discovery process. In detail, we distinguish between molecules that are selective toward one single protein and other compounds that are active on multiple targets. In this way, it is possible to identify which molecular properties enhance target selectivity and which protein families are likely to constitute off-targets.

Materials and Methods {#s1}
=====================

Ligand Dataset Retrieval
------------------------

We extracted the set of 139,352 DCM compounds from Novartis and PubChem ([@B16]) as InChi (IUPAC International Chemical Identifier) from the Supporting Information of [@B50] and downloaded the 3D coordinates of 139,328 molecules from the PubChem Compound database ([@B17]).

The set of active compounds was extracted from PubChem BioAssay ([@B49]) using the list of 459 bioassays provided by [@B50]. Active compounds (256,448) were extracted via their compound identifiers (CIDs), downloaded as 3D coordinates (237,510) and pooled to a single set of 376,838 compounds.

Furthermore, we performed a filtering step to remove duplicates within the dataset. To this purpose we used the RDKit ([@B37]) chemoinformatics toolkit. Moreover, we removed the compounds that were active but without any specified targets (14,464). Our final dataset included 341,599 molecules.

Computation of Molecular Descriptors
------------------------------------

The PubChem coordinate files contained already precomputed 2D descriptors, including MW, number of heavy atoms, defined and undefined stereocenters, H-bond donors and acceptors, which were considered for our analysis as provided.

Additionally, we calculated logS ([@B13]) and logP~(o/w)~ using the MOE (Molecular Operating Environment, version 2015.1001) ([@B27]) molecular descriptor tools and the atomic geometries with MOE's Scientific Vector Language (SVL) function "aGeometry" together with the SMARTS matching function "sm_MatchAll." In detail, aGeometry returns the hybridization of an atom and sm_MatchAll searches for specific SMARTS patterns, which we used to count non-ring and non-terminal carbon atoms. For instance, sp^3^ carbon atoms are counted by matching "CH~2~" SMARTS codes. In order to restrict the count to non-ring and non-terminal atoms, we specified "!r" and "!H~3~" respectively.

Furthermore, we used RDKit ([@B37]) to count the number of single and fused aromatic and aliphatic rings as well as the number of carbon--carbon and carbon--nitrogen double bonds based on SMILES codes.

Statistical analysis, including the two-sided Wilcoxon rank-sum test and Kolmogorov--Smirnov test, was performed using R ([@B34]) (Supplementary Tables [2](#SM1){ref-type="supplementary-material"}--[4](#SM1){ref-type="supplementary-material"}).

Target Retrieval and Analysis
-----------------------------

Assay and target information for all compounds have been retrieved from the PubChem database by querying the compounds identifiers (CID) against the assay summary webpage. Active targets with specified gene id were considered for Uniprot ([@B3]; [@B45]) retrieval, in order to convert the gene id to the associated protein's Uniprot accession number.

We assigned the protein superfamily for every target, by searching Uniprot accession numbers into lists of GPCRs, kinases, proteases, and ion channels. We obtained the lists of 3,092 GPCRs, 1,365 kinases and 11,606 proteases from Uniprot, and the list of 899 ion channels from ChEMBL ([@B4]) and IUPHAR/BPS Guide to Pharmacology ([@B43]).

We counted the number of targets on which a molecule is found to be active and clustered active ligands in three classes: black compounds are active only on one single target, gray compounds are active on two to four targets and white compounds are active on more than four targets. We defined these cut-off values in order to obtain a comparable number of molecules in every subset: 73,383 black, 103,025 gray, 87,303 white, 77,888 inactive compounds (compound set provided via SI).

Figures are generated by using MATLAB ([@B25]), R ([@B34]) and ChemDraw ([@B31]).

Results
=======

Molecular Descriptors
---------------------

We analyzed the distributions of 2D molecular descriptors within the compound sets (inactive, black, gray, and white). We find that chirality enhances target selectivity. For instance, molecules become more selective if they present at least one chiral center: inactive and black compounds contain a higher number of defined R/S stereocenters with respect to white molecules (**Figure [1A](#F1){ref-type="fig"}**). On the contrary, the absence of a chiral center enhances promiscuity, as described by the percentage of white molecules (∼79% versus ∼62% in black ones) (Supplementary Table [1](#SM1){ref-type="supplementary-material"}).

![Statistical analysis of molecular descriptors per ligand class (inactive, black, gray, and white). Data are represented as 3D bar plots, colored according to the percentage values for each subset (see color bar). **(A)** The number of R/S stereocenters per molecule shows that most of white compounds have no chiral centers, whereas inactive molecules show the highest percentage of compounds with one stereocenter. **(B)** The number of carbon--carbon or carbon--nitrogen double bonds is higher for white ligands compared to the other classes, which normally have none. **(C)** Inactive and black sets exhibit higher content of non-ring and non-terminal sp^3^ carbon atoms with respect to white compounds, which tend to be sp^2^ hybridized. **(D)** The molecular weight (MW) is similar for all subsets in the range 300--500 Da, but shows different results for smaller and higher values. Indeed, inactive and white compounds exhibit higher percentages for values lower than 300 Da, with respect to black and gray sets. On the contrary, black compounds can be rather complex structures as their MW can be higher than 500 Da. The MW axis is divided into different ranges and its labels represent the highest boundary. For instance, "350" indicates compounds with MW values between 300 and 350. **(E)** Most of white molecules have no aliphatic rings, which characterize instead inactive and black datasets. **(F)** In contrast, a higher number of fused aromatic rings is a chemical feature of white molecules.](fphar-08-00552-g001){#F1}

On the opposite, if at least a carbon--carbon or carbon--nitrogen double bond is present, molecules tend to be white and, hence, more promiscuous (**Figure [1B](#F1){ref-type="fig"}**). Otherwise, if they do not have any double bonds, they tend to be inactive or black (∼85% versus ∼69% in white ones) (Supplementary Table [1](#SM1){ref-type="supplementary-material"}).

These findings are also confirmed by the analysis of atomic geometries: non-ring and non-terminal sp^3^ carbon atoms enhance selectivity (**Figure [1C](#F1){ref-type="fig"}**); about 42% of white compounds do not include any sp^3^ carbon atoms, with respect to ∼27% of inactive and black ones (Supplementary Table [1](#SM1){ref-type="supplementary-material"}).

We also computed the molecular descriptors that were reported by [@B50]. However, our results show that the MW is not able to properly describe target selectivity: indeed, black compounds do not follow the expected trend, as they show MWs which are comparable to those of white molecules (**Figure [1D](#F1){ref-type="fig"}**). This finding disagrees with [@B50], because our dataset does not include all molecules that were considered in the Novartis analysis, but only those that were reported in the publication. As this descriptor appears dataset dependent, we discarded it.

Additionally, the number of rings differs between these classes: black compounds exhibit higher numbers of aliphatic rings (∼36% of black molecules have one aliphatic ring, with respect to 30% of white ones) (**Figure [1E](#F1){ref-type="fig"}**). By constrast, white compounds show higher numbers of fused aromatic rings (∼35% with respect to 26% of inactive molecules) (**Figure [1F](#F1){ref-type="fig"}**). Indeed, more than half of the selective molecules has at least one aliphatic ring (∼53% of inactive and ∼51% of black compounds) and no fused aromatic rings (∼71 of inactive and 62% of black compounds).

Furthermore, inactive and black compounds exhibit higher values of logS compared to gray and white compounds, especially for logS in the range between -2 and -4 (**Figure [2A](#F2){ref-type="fig"}**). By contrast, the opposite trend is observed for lower solubility: half of white molecules shows a logS value lower than -5, whereas only 20% of inactive and ∼30% of black compounds have similar solubility (Supplementary Table [1](#SM1){ref-type="supplementary-material"}).

![Statistical analysis of molecular solubility (logS) and hydrophobicity (SlogP) per ligand class (inactive, black, gray, and white). Data are represented as 3D bar plots, colored according to the percentage values for each subset (see color bar). The logS and SlogP axes are divided into different ranges and labels represent the highest boundary of each range. **(A)** Molecular solubility, reported as logS, is higher for inactive and black compounds for values higher than *--*4. Whereas white compounds have logS values lower than *--*4. **(B)** White compounds show SlogP values higher than 4. In contrast, inactive and black molecules have values lower than 4.](fphar-08-00552-g002){#F2}

Consequently, lipophilicity increases with the number of targets: gray and white molecules show higher SlogP values than inactive and black ones (**Figure [2B](#F2){ref-type="fig"}**). For instance, ∼36% of white compounds show SlogP values that are higher than 4, whereas selective molecules (∼33% of inactive and ∼29% of black compounds) exhibit SlogP values which are in the range between 2 and 3.

Calculating these molecular descriptors, it is possible to predict which building blocks characterize black compounds and, therefore, can be used for synthesis of new selective drug candidates.

Target Analysis
---------------

Our dataset includes ligands that bind to a variety of targets, 2,715 in total. For instance, 10.98% of the targets are represented by G-protein coupled receptors (GPCRs), 13.41% by kinases, 10.68% by ion channels and 5.78% by proteases (**Figure [3](#F3){ref-type="fig"}**). About 60% of the targets comprise other enzymes, receptors or transcription factors that do not fall into these four major target classes.

![Statistical analysis of targets that are present in the entire dataset. In total, we identified 2,715 different targets. GPCRs represent 10.98%, kinases 13.41%, ion channels 10.68%, and proteases 5.78%. Other targets include further enzymes, nuclear receptors, and transcription factors.](fphar-08-00552-g003){#F3}

G-protein coupled receptor ligands are more selective than other classes, as the number of black compounds is higher (14.30%) with respect to other targets (5.80% ion channels, 6.25% ion channels, 9.21% kinases) (**Figure [4](#F4){ref-type="fig"}**). For example, CID 2983576 is a ligand that binds to the human cholinergic muscarinic receptor 4 and is inactive toward other muscarinic receptor subtypes (**Figure [5](#F5){ref-type="fig"}**). As many other black compounds, it contains a chiral center, an aliphatic ring, several non-ring and non-terminal sp^3^ carbon atoms (5) and has a low logP value (2.2).

![Distribution of black, gray, and white compounds in every target class. The number of black compounds is higher for GPCR ligands (14.30%) compared to other targets (5.80% ion channels, 6.25% ion channels, 9.21% kinases). In contrast, ion channels and proteases have higher percentages of white molecules.](fphar-08-00552-g004){#F4}

![Ligands that represent the dataset. Compounds are labeled according to the compound identifier (CID) from PubChem. CID 2983576 is a selective GPCR ligand: its absolute stereochemistry is undefined in PubChem and, hence, not shown here. CID 646260 is a protease ligand, which binds also to other non-protease targets. CID 1005278 is a kinase ligand that binds also to other non-kinase targets. CID 2283311 is a selective kinase ligand that is active only on one target.](fphar-08-00552-g005){#F5}

Ligands that bind to ion channels and proteases tend to be more promiscuous (**Figure [4](#F4){ref-type="fig"}**). This is particularly pronounced for proteases, where 62% of ligands can bind to more than four non-protease targets (**Figure [6](#F6){ref-type="fig"}**). For example, CID 646260 is active on caspase 3 and other non-protease targets, such as GPCRs and other enzymes.

![Number of targets hit by every ligand class (GPCRs, kinases, ion channels, and proteases). The first row shows if ligands can hit other targets that are not included in their own target class: for instance, GPCR ligands might hit only GPCRs (indicated as "0 off-targets") or also other non-GPCR targets (larger number of off-targets). The following rows of pie charts show the number of ligands that hit a specific target class: for instance, GPCR ligands hit at least one GPCR, whereas kinase or ion channel or protease ligands can hit GPCRs or not (indicated as "0 GPCRs"). The same is shown for all four target classes. Intra-class selectivity is highlighted by colored boxes around the pie charts.](fphar-08-00552-g006){#F6}

In contrast, only 37% of GPCR ligands binds to other proteins beyond GPCRs. For instance, only 13% of GPCR ligands bind to kinases, 16% to proteases and 24% to ion channels.

Instead, kinase ligands are able to bind to many non-kinase targets. For example, compound CID 1005278 binds not only to kinases (such as RIPK), but also to potassium channels (such as KCNQ1), dopamine receptors (D1 and D3), proteases and other non-kinase targets. However, analysis of intra-class activity shows that kinase ligands in general bind only to one kinase (for example, CID 2283311 is a black molecule that is active only on MAP3K3). This evidence is surprising, as kinases are known to be promiscuous, especially toward other kinases ([@B7]). However, the number of kinase ligands in our dataset is relatively small (27,935) and we might miss information from unselective ligands that were not included in the analysis.

Furthermore, ion channel, protease and kinase ligands exhibit higher chances to bind to GPCRs: almost half of ion channel (49%), 36.6% of protease and 35% of kinase ligands bind to GPCRs as well. However, this trend cannot be observed for proteases, kinases or ion channels, as they exhibit lower probabilities to bind to these target classes (Supplementary Figure [2](#SM1){ref-type="supplementary-material"}).

Discussion
==========

The escape from flatland has already been described as a valuable approach to improve clinical success ([@B23]) and the unique activity profiles of highly potent and selective molecules might be the underlying principle. It is chemically intuitive that more complex molecular shapes restrict the diversity of binding partners and provide selectivity gains ([@B26]). A criterion favoring complex 3D shapes, with chiral centers and high sp^3^ carbon contents, low number of double bonds and fused aromatic rings, in candidate molecules might complement widely accepted criteria for drug-likeness solely based on 2D molecular properties, like solubility and MW ([@B21]; [@B19]).

We also believe that these molecular properties highly affect the target selectivity. Indeed, already [@B23] stated that the degree of saturation is able to distinguish marketed drugs from drug-like molecules. In detail, compounds that have success through clinical trials are characterized by increased saturation and the presence of chiral centers. For instance, our findings confirm that the sp^3^ conformation is a key feature to obtain target selectivity and in turn to improve clinical success in the process of drug development.

These molecular descriptors, together with solubility and lipophilicity, may be readily applied as an additional selection criterion for promising starting points in early stage drug discovery. [@B50] have shown DCM is more soluble than active molecules. Our results are in agreement with their findings, as selective compounds are more soluble than promiscuous ones.

In contrast, MW does not properly distinguish between inactive and white molecules as shown in other datasets. For instance, promiscuity is enhanced by lower values of MW in a dataset from Pfizer ([@B12]), but higher values in datasets from Novartis ([@B2]), Roche ([@B33]) and Boehringer Ingelheim ([@B29]).

We also considered further molecular descriptors, such as the number of hydrogen bond donors and acceptors, but they do not allow to distinguish between selective and promiscuous compounds (Supplementary Table [1](#SM1){ref-type="supplementary-material"}), as also shown by Novartis ([@B2]) and Roche ([@B33]).

In our dataset many ligands are promiscuous and, hence, can effectively hit off-targets, which are represented by all other targets that a molecule can bind besides the intended target ([@B41]).

However, in our dataset GPCR ligands are highly selective. This evidence appears to be in contrast to previous knowledge, as GPCRs are known to be promiscuous targets, especially if their ligands are not peptidic or small molecules ([@B30]). For instance, our results may change by considering specialized datasets, such as PDSP Ki database ([@B40]).

Additionally, our analysis shows that ligands from other target protein families can easily bind GPCRs. Indeed, there are great overlaps between all four target classes that we considered (Supplementary Figure [2](#SM1){ref-type="supplementary-material"}) and we do not know if these molecules were developed firstly as GPCR ligands or not.

The identification of a GPCR as off-target is extremely important, as the activity on specific GPCRs is also related to severe side effects, e.g., cardiovascular diseases. Indeed, 5-HT2B has been identified as cause of valvulopathy and led to the withdrawal of drugs from the market ([@B14]).

Our results show that protease ligands can bind to many off-targets: indeed, it can be difficult to achieve target selectivity within related proteases ([@B9]) but strategies to rationally improve the selectivity profiles of protease inhibitors based on substrate peptide data and experimental 3D structures have been described ([@B10]).

In our dataset, kinase ligands seem to be selective toward only one kinase member rather than to more targets in the same protein family. However, this unexpected outcome can be explained by the relatively low amount of kinases ligands that is present in the dataset. Kinase ligands are indeed generally known to be promiscuous, but some of them exhibit higher selectivity, especially if they bind to the pocket close to the ATP site and prefer a specific conformation of the activation loop ([@B7]). Moreover, in our dataset we identify even more pronounced polypharmacology within and between other target classes. For instance, ion channel ligands overlap with GPCR ligands, as they frequently exhibit a common ligand scaffold, which includes an amine linked to an aromatic ring by an alkylic chain that is present in benzodiazepines or dihydropyridines. In addition, ion channels constitute a common off-target, causing cardiac adverse effects. Indeed, hERG potassium channels are responsible of arrhythmias, in particular torsades de pointes, and many antipsychotics and other drugs bind to these channels as off-targets, increasing the risk of cardiovascular diseases ([@B42]). As example, the antihistaminic terfenadine was withdrawn from the market for its toxic adverse effect, that was caused by this off-target activity ([@B28]).

This analysis bring us to ask if we can identify likely off-targets in the early discovery process. Normally, in the early steps, target selectivity is considered only among related targets, which are proteins that belong to the same protein family, since high structure and ligand similarity is expected. In this case, target selectivity can be rationalized, e.g., via X-ray structures of targets and off-targets. However, several adverse side effects are caused by distant or nearly unrelated targets. For this reason, the prediction of ligand binding is still challenging and the use of cheminformatics tools can guide the medicinal chemists in identifying the chemical features that typically cause promiscuity ([@B5]). Nevertheless, the training of virtual screening models is limited by the use of biased ligand sets. Indeed, our analysis show that results highly depend on the selected dataset, which affected the distribution of the physico-chemical properties and target classes. Therefore we expect that based on the desired target, specialized datasets can be used to further improve the performance of *in silico* models.

In particular, screening libraries can be properly designed by taking into account molecular properties, such as stereochemistry, atomic geometries and rings, besides solubility and lipophilicity. Many predesigned compound libraries are already freely available online and could be easily filtered or prioritized by using these 2D descriptors, without the need of applying a time consuming and computationally demanding generation of 3D conformers.

Conclusion
==========

A good starting point for the design of a selective drug should favor aliphatic over aromatic rings, alkylic chains containing sp^3^ carbon atoms over double bonds, and stereocenters over achiral atoms. Even though the introduction of chiral centers can make the synthesis more challenging, the gain in target selectivity may be considerable.

On the other hand, polypharmacology could be achieved by introducing flat chemical moieties, such as fused aromatic rings and double bonds. However, this could bring not only additional desired, but also undesired side effects.
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